CD28, CTLA-4 and their ligands: who does what and to whom?
about
Are Microglial Cells the Regulators of Lymphocyte Responses in the CNS?The PD1:PD-L1/2 Pathway from Discovery to Clinical ImplementationInduction of specific T-cell responses, opsonizing antibodies, and protection against Plasmodium chabaudi adami infection in mice vaccinated with genomic expression libraries expressed in targeted and secretory DNA vectors.Telomere/telomerase dynamics within the human immune system: effect of chronic infection and stress.Identification of the neoplastically transformed cells in Marek's disease herpesvirus-induced lymphomas: recognition by the monoclonal antibody AV37.Osteoprotegerin.The critical role of antigen-presentation-induced cytokine crosstalk in the central nervous system in multiple sclerosis and experimental autoimmune encephalomyelitis.Constitutive clathrin-mediated endocytosis of CTLA-4 persists during T cell activation.Expression and purification of soluble porcine CTLA-4 in yeast Pichia pastoris.A Potential Inhibitory Profile of Liver CD68+ Cells during HCV Infection as Observed by an Increased CD80 and PD-L1 but Not CD86 Expression.CD28 family and chronic rejection: "to belatacept...And beyond!".Increased CD86 but Not CD80 and PD-L1 Expression on Liver CD68+ Cells during Chronic HBV Infection.CTLA4 gene polymorphism and autoimmunity.The role of the CTLA4 blockade in the treatment of malignant melanoma.Radiotherapy and immune checkpoint blockades: a snapshot in 2016.Tumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy.MODULATING CO-STIMULATION DURING ANTIGEN PRESENTATION TO ENHANCE CANCER IMMUNOTHERAPY.Treg and CTLA-4: two intertwining pathways to immune tolerance.Understanding the CD28/CTLA-4 (CD152) pathway and its implications for costimulatory blockade.A single cell density-sensing factor stimulates distinct signal transduction pathways through two different receptors.The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date.Stimulating immune responses to fight cancer: Basic biology and mechanisms.Prospective Preliminary In Vitro Investigation of a Magnetic Iron Oxide Nanoparticle Conjugated with Ligand CD80 and VEGF Antibody As a Targeted Drug Delivery System for the Induction of Cell Death in Rodent Osteosarcoma Cells.Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy.Increased Expression of Cytotoxic T-Lymphocyte-Associated Protein 4 by T Cells, Induced by B7 in Sera, Reduces Adaptive Immunity in Patients With Acute Liver Failure.Autoimmune disease-associated haplotypes of BLK exhibit lowered thresholds for B cell activation and expansion of Ig class-switched B cells.Expression of CTLA-4 by human monocytes.Molecular basis of cross-species reactivities of human versus porcine CTLA-4.The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses.Clinical safety of combined therapy of immune checkpoint inhibitors and Viscum album L. therapy in patients with advanced or metastatic cancer.Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade.Immune Checkpoint Inhibitor-Associated Type 1 Diabetes Mellitus: Case Series, Review of the Literature, and Optimal Management.TIGIT expressing CD4+T cells represent a tumor-supportive T cell subset in chronic lymphocytic leukemia.Differential expression of CTLA-4 among T cell subsets.Linked CD4 T Cell Help: Broadening Immune Attack Against Cancer by Vaccination.A mathematical modelling tool for unravelling the antibody-mediated effects on CTLA-4 interactions.Characterization of CTLA4 Trafficking and Implications for Its FunctionInhibition of RON kinase potentiates anti-CTLA-4 immunotherapy to shrink breast tumors and prevent metastatic outgrowthCTLA-4 and PD-1 Ligand Gene Expression in Epithelial Thyroid CancersAssociations between autoimmune thyroid disease prognosis and functional polymorphisms of susceptibility genes, CTLA4, PTPN22, CD40, FCRL3, and ZFAT, previously revealed in genome-wide association studies
P2860
Q26774826-0C5F44A7-39EC-4430-83CC-341D16E0795FQ28066941-E1453ADF-ECD0-45AB-A111-625EBFC0DD6EQ30783460-D47DB234-B3EF-4DDA-BE31-362D44A6AB0AQ34137354-F07DF610-D6CA-4824-AC27-6FE77E7FAD03Q34341797-D7DE53AC-1E5C-444A-B6DD-E225AD2C5449Q34560598-BA6BBEA1-B3A7-400B-A349-183265C8B846Q35294476-C835F503-9F81-40F8-A198-390148D9EC4FQ35842036-EECF478D-1151-446B-B2E5-28286CE8276DQ35869706-204813E1-1634-46A1-B1DC-7CBE5991E046Q35985861-C06663F9-2367-48FB-A649-4C0256AEB3F6Q36037639-0911F512-1ECC-4500-8CAE-91D0429816ACQ36062362-7AE6B127-4C1D-4F9A-AF95-A6B5269C09F2Q36079873-F5A8FA37-564F-4F65-BB1D-CA1AB2983A1FQ37008621-5716FCB6-4190-43BF-BFC2-B5B1499E2A09Q37551762-65A77C11-4E0D-417F-853A-A3B344E5787AQ37635491-30891C40-2A43-4673-B92E-0CE408900105Q38040302-7A03DFD4-9620-4335-91A5-8FB983C72FEFQ38121260-1F742AEB-2D65-4EFC-B477-A42BD418AFF0Q38237428-94E79E1D-DF4A-4037-B093-565E17EC861BQ38288048-2374F7D7-5D60-4EB4-8257-B95843F3512BQ38388590-6C29513D-3EED-4F8A-85FE-1E3BA41AD3D6Q38578898-7C610FDE-933D-43C8-A5A2-89BDFBE5D0A5Q38731083-32507801-CE51-40FF-AF61-138F46D9F05FQ39161011-A9C4D8BD-5F54-4106-8A89-4D54E80D5A3EQ40270051-86A5A672-F2AF-4F54-9134-A90D80B609D7Q40656429-FEF218E5-2CFF-40E4-A177-3E53846B1493Q40751320-B0440E51-3B56-41FD-93D4-B8C84BF7CDE8Q43077410-4B568730-86A3-4E20-B081-12D86908025CQ44393406-1164702A-EDD5-44C8-B586-8F35F3CEDCB8Q47094041-D2E6EC76-C3C5-4AB6-ADDA-DC9CE945549CQ47135020-6B073784-042A-4F8A-BA64-8CDAAAD0A866Q47146381-EC1BAB34-8807-4F1B-8B26-8B4414AD7E38Q47217185-BB88915E-F422-4B6D-900E-95021519087FQ47594359-8FAEC73E-3F20-47AD-AAC7-7E18EDD85089Q49013708-38841278-94C3-43FB-93C6-CC9D46BC0760Q55336684-AFAAB932-59F6-4240-B529-73D5C9E57445Q56889794-A6772F9E-A88A-45B8-98C2-1740A94B188CQ56891079-18AAE3D1-7DCF-4644-BD84-324F9A69E1EBQ56891239-EBE3FFB9-074B-4E20-9949-C426105A359DQ56897699-7252F29A-AA59-4D6D-AAB2-EB4CA56387D7
P2860
CD28, CTLA-4 and their ligands: who does what and to whom?
description
2000 nî lūn-bûn
@nan
2000 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
CD28, CTLA-4 and their ligands: who does what and to whom?
@ast
CD28, CTLA-4 and their ligands: who does what and to whom?
@en
CD28, CTLA-4 and their ligands: who does what and to whom?
@nl
type
label
CD28, CTLA-4 and their ligands: who does what and to whom?
@ast
CD28, CTLA-4 and their ligands: who does what and to whom?
@en
CD28, CTLA-4 and their ligands: who does what and to whom?
@nl
prefLabel
CD28, CTLA-4 and their ligands: who does what and to whom?
@ast
CD28, CTLA-4 and their ligands: who does what and to whom?
@en
CD28, CTLA-4 and their ligands: who does what and to whom?
@nl
P2860
P1433
P1476
CD28, CTLA-4 and their ligands: who does what and to whom?
@en
P2093
D M Sansom
P2860
P304
P356
10.1046/J.1365-2567.2000.00121.X
P577
2000-10-01T00:00:00Z